poisar

Stocks · News reference

Sanofi Drops Dupixent Successor Candidate After Assessing Data

Jul 24, 2026, 6:10 PMVandana Singh

Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

REGNSNY
Source
benzinga
Observed
Jul 24, 2026, 6:10 PM
Checked
Jul 24, 2026, 6:10 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 21, 2026, 11:02 AMAndy Gould

    IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

    The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

    Read original at the-motley-fool
    AMGNVRTXREGN
  5. Aug 26, 2026, 1:44 PMResearchandmarkets.Com

    $7+ Billion mRNA Vaccines Market Outlook, 2035: Opportunities, Strategies, Challenges

    The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

    Read original at globenewswire-inc
    MRNABNTXPFESNY
  6. Aug 25, 2026, 4:46 PMBcc Research

    AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

    Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

    Read original at globenewswire-inc
    MRKRHHBYBMYCELGRNVS